Laakmann G, Munz T, Hinz A, Voderholzer U
Psychiatric Hospital, University of Munich, Germany.
Psychoneuroendocrinology. 1990;15(5-6):391-9. doi: 10.1016/0306-4530(90)90064-g.
We report herein the effects of the beta-adrenergic agonist clenbuterol on desipramine (DMI)-induced growth hormone (GH), prolactin (PRL) and cortisol secretion in healthy male subjects. In the first study, nine subjects were treated with either clenbuterol (0.04 mg, p.o.) or placebo. In the second study, 12 subjects received either DMI (50 mg, i.v.) alone or in combination with clenbuterol (0.04 mg, p.o.) given 60 min prior to DMI administration. Clenbuterol alone had no influence on GH, PRL, or cortisol concentrations, compared to placebo. DMI alone caused GH stimulation (mean maximum = 15.7 +/- 3.4 ng/ml), which was significantly lower after combined administration of DMI and clenbuterol (mean maximum = 7.7 +/- 1.6 ng/ml) (p less than or equal to 0.01). DMI-induced PRL and cortisol stimulation was not influenced by clenbuterol pretreatment. These results indicate the inhibiting influence of noradrenergic beta-receptors on GH stimulation.
我们在此报告β-肾上腺素能激动剂克仑特罗对健康男性受试者中地昔帕明（DMI）诱导的生长激素（GH）、催乳素（PRL）和皮质醇分泌的影响。在第一项研究中，9名受试者接受了克仑特罗（0.04毫克，口服）或安慰剂治疗。在第二项研究中，12名受试者单独接受DMI（50毫克，静脉注射）或在DMI给药前60分钟联合接受克仑特罗（0.04毫克，口服）。与安慰剂相比，单独使用克仑特罗对GH、PRL或皮质醇浓度没有影响。单独使用DMI可引起GH刺激（平均最大值 = 15.7 +/- 3.4纳克/毫升），在联合使用DMI和克仑特罗后显著降低（平均最大值 = 7.7 +/- 1.6纳克/毫升）（p小于或等于0.01）。DMI诱导的PRL和皮质醇刺激不受克仑特罗预处理的影响。这些结果表明去甲肾上腺素能β受体对GH刺激有抑制作用。
